A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: Impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids

Mark Underwood, Nita H. Salzman, Stephen H. Bennett, Melissa Barman, David A. Mills, Angela Marcobal, Daniel J Tancredi, Charles L Bevins, Michael P. Sherman

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

OBJECTIVE:: To compare the effect of 2 prebiotic/probiotic products on weight gain, stool microbiota, and stool short-chain fatty acid (SCFA) content of premature infants. PATIENTS AND METHODS:: This randomized, blinded, placebo-controlled trial included 90 premature infants treated with either a dietary supplement containing 2 lactobacillus species plus fructooligosaccharides (CUL, Culturelle, ConAgra, Omaha, NE), a supplement containing several species of lactobacilli and bifidobacteria plus fructooligosaccharides (PBP, ProBioPlus DDS, UAS Laboratories, Eden Prairie, MN), or placebo (a dilute preparation of Pregestamil formula) twice daily for 28 days or until discharge if earlier. The primary outcome was weight gain. Secondary outcomes were stool bacterial analysis by culture and 16S rDNA quantitative polymerase chain reaction and stool SCFA content measured by high performance liquid chromatography. RESULTS:: Both prebiotic/probiotic combinations contained more bacterial species than noted on the label. No significant effect on infant growth of either prebiotic/probiotic supplement was observed. By cultures, 64% of infants receiving PBP became colonized with bifidobacteria, compared with 18% of infants receiving CUL and 27% of infants receiving placebo (chi-square, P = 0.064). No differences were noted between groups in colonization rates for lactobacilli, Gram-negative enteric bacteria, or staphylococci. By 16S rDNA polymerase chain reaction analysis, the bifidobacteria content in the stools of the infants receiving PBP was higher than in the infants receiving CUL or placebo (Kruskal-Wallis, P = 0.011). No significant differences in stool SCFA content were detected between groups. No adverse reactions were noted. CONCLUSIONS:: Infants receiving PBP were more likely to become colonized with bifidobacteria. No significant differences in weight gain or stool SCFA content were detected.

Original languageEnglish (US)
Pages (from-to)216-225
Number of pages10
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume48
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Prebiotics
Volatile Fatty Acids
Probiotics
Premature Infants
Weight Gain
Placebos
Bifidobacterium
Lactobacillus
Ribosomal DNA
Lactobacillus rhamnosus
Polymerase Chain Reaction
Microbiota
Enterobacteriaceae
Dietary Supplements
Gastrointestinal Microbiome
Gram-Negative Bacteria
Staphylococcus
High Pressure Liquid Chromatography
Growth

Keywords

  • Microflora
  • Prebiotic
  • Premature infant
  • Probiotic
  • Synbiotic

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants : Impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. / Underwood, Mark; Salzman, Nita H.; Bennett, Stephen H.; Barman, Melissa; Mills, David A.; Marcobal, Angela; Tancredi, Daniel J; Bevins, Charles L; Sherman, Michael P.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 48, No. 2, 02.2009, p. 216-225.

Research output: Contribution to journalArticle

@article{5f0e4995ea604d8faea2d6fbbc6f0eba,
title = "A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: Impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids",
abstract = "OBJECTIVE:: To compare the effect of 2 prebiotic/probiotic products on weight gain, stool microbiota, and stool short-chain fatty acid (SCFA) content of premature infants. PATIENTS AND METHODS:: This randomized, blinded, placebo-controlled trial included 90 premature infants treated with either a dietary supplement containing 2 lactobacillus species plus fructooligosaccharides (CUL, Culturelle, ConAgra, Omaha, NE), a supplement containing several species of lactobacilli and bifidobacteria plus fructooligosaccharides (PBP, ProBioPlus DDS, UAS Laboratories, Eden Prairie, MN), or placebo (a dilute preparation of Pregestamil formula) twice daily for 28 days or until discharge if earlier. The primary outcome was weight gain. Secondary outcomes were stool bacterial analysis by culture and 16S rDNA quantitative polymerase chain reaction and stool SCFA content measured by high performance liquid chromatography. RESULTS:: Both prebiotic/probiotic combinations contained more bacterial species than noted on the label. No significant effect on infant growth of either prebiotic/probiotic supplement was observed. By cultures, 64{\%} of infants receiving PBP became colonized with bifidobacteria, compared with 18{\%} of infants receiving CUL and 27{\%} of infants receiving placebo (chi-square, P = 0.064). No differences were noted between groups in colonization rates for lactobacilli, Gram-negative enteric bacteria, or staphylococci. By 16S rDNA polymerase chain reaction analysis, the bifidobacteria content in the stools of the infants receiving PBP was higher than in the infants receiving CUL or placebo (Kruskal-Wallis, P = 0.011). No significant differences in stool SCFA content were detected between groups. No adverse reactions were noted. CONCLUSIONS:: Infants receiving PBP were more likely to become colonized with bifidobacteria. No significant differences in weight gain or stool SCFA content were detected.",
keywords = "Microflora, Prebiotic, Premature infant, Probiotic, Synbiotic",
author = "Mark Underwood and Salzman, {Nita H.} and Bennett, {Stephen H.} and Melissa Barman and Mills, {David A.} and Angela Marcobal and Tancredi, {Daniel J} and Bevins, {Charles L} and Sherman, {Michael P.}",
year = "2009",
month = "2",
doi = "10.1097/MPG.0b013e31818de195",
language = "English (US)",
volume = "48",
pages = "216--225",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants

T2 - Impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids

AU - Underwood, Mark

AU - Salzman, Nita H.

AU - Bennett, Stephen H.

AU - Barman, Melissa

AU - Mills, David A.

AU - Marcobal, Angela

AU - Tancredi, Daniel J

AU - Bevins, Charles L

AU - Sherman, Michael P.

PY - 2009/2

Y1 - 2009/2

N2 - OBJECTIVE:: To compare the effect of 2 prebiotic/probiotic products on weight gain, stool microbiota, and stool short-chain fatty acid (SCFA) content of premature infants. PATIENTS AND METHODS:: This randomized, blinded, placebo-controlled trial included 90 premature infants treated with either a dietary supplement containing 2 lactobacillus species plus fructooligosaccharides (CUL, Culturelle, ConAgra, Omaha, NE), a supplement containing several species of lactobacilli and bifidobacteria plus fructooligosaccharides (PBP, ProBioPlus DDS, UAS Laboratories, Eden Prairie, MN), or placebo (a dilute preparation of Pregestamil formula) twice daily for 28 days or until discharge if earlier. The primary outcome was weight gain. Secondary outcomes were stool bacterial analysis by culture and 16S rDNA quantitative polymerase chain reaction and stool SCFA content measured by high performance liquid chromatography. RESULTS:: Both prebiotic/probiotic combinations contained more bacterial species than noted on the label. No significant effect on infant growth of either prebiotic/probiotic supplement was observed. By cultures, 64% of infants receiving PBP became colonized with bifidobacteria, compared with 18% of infants receiving CUL and 27% of infants receiving placebo (chi-square, P = 0.064). No differences were noted between groups in colonization rates for lactobacilli, Gram-negative enteric bacteria, or staphylococci. By 16S rDNA polymerase chain reaction analysis, the bifidobacteria content in the stools of the infants receiving PBP was higher than in the infants receiving CUL or placebo (Kruskal-Wallis, P = 0.011). No significant differences in stool SCFA content were detected between groups. No adverse reactions were noted. CONCLUSIONS:: Infants receiving PBP were more likely to become colonized with bifidobacteria. No significant differences in weight gain or stool SCFA content were detected.

AB - OBJECTIVE:: To compare the effect of 2 prebiotic/probiotic products on weight gain, stool microbiota, and stool short-chain fatty acid (SCFA) content of premature infants. PATIENTS AND METHODS:: This randomized, blinded, placebo-controlled trial included 90 premature infants treated with either a dietary supplement containing 2 lactobacillus species plus fructooligosaccharides (CUL, Culturelle, ConAgra, Omaha, NE), a supplement containing several species of lactobacilli and bifidobacteria plus fructooligosaccharides (PBP, ProBioPlus DDS, UAS Laboratories, Eden Prairie, MN), or placebo (a dilute preparation of Pregestamil formula) twice daily for 28 days or until discharge if earlier. The primary outcome was weight gain. Secondary outcomes were stool bacterial analysis by culture and 16S rDNA quantitative polymerase chain reaction and stool SCFA content measured by high performance liquid chromatography. RESULTS:: Both prebiotic/probiotic combinations contained more bacterial species than noted on the label. No significant effect on infant growth of either prebiotic/probiotic supplement was observed. By cultures, 64% of infants receiving PBP became colonized with bifidobacteria, compared with 18% of infants receiving CUL and 27% of infants receiving placebo (chi-square, P = 0.064). No differences were noted between groups in colonization rates for lactobacilli, Gram-negative enteric bacteria, or staphylococci. By 16S rDNA polymerase chain reaction analysis, the bifidobacteria content in the stools of the infants receiving PBP was higher than in the infants receiving CUL or placebo (Kruskal-Wallis, P = 0.011). No significant differences in stool SCFA content were detected between groups. No adverse reactions were noted. CONCLUSIONS:: Infants receiving PBP were more likely to become colonized with bifidobacteria. No significant differences in weight gain or stool SCFA content were detected.

KW - Microflora

KW - Prebiotic

KW - Premature infant

KW - Probiotic

KW - Synbiotic

UR - http://www.scopus.com/inward/record.url?scp=66149153878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149153878&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e31818de195

DO - 10.1097/MPG.0b013e31818de195

M3 - Article

C2 - 19179885

AN - SCOPUS:66149153878

VL - 48

SP - 216

EP - 225

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 2

ER -